Finerenone for Cardiorenal Protection in Diabetic CKD: Impact on Renal Function Decline and Heart Failure

Inclusion Criteria: * Adults aged ≥18 years. * Diagnosed cases of type 2 diabetes mellitus. * Chronic kidney disease with eGFR 25-90 mL/min/1.73m² and/or UACR ≥30 mg/g. * On stable ACE inhibitor or ARB therapy for at least 4 weeks. * Serum potassium ≤4.8 mmol/L. * Provided written informed consent. Exclusion Criteria: * Symptomatic heart failure (NYHA class II-IV). * eGFR \<25 mL/min/1.73m² or on maintenance dialysis. * Known non-diabetic kidney disease. * Recent major cardiovascular event (within 30 days). * Serum potassium \>4.8 mmol/L or history of severe hyperkalaemia. * Contraindication or hypersensitivity to finerenone. * Pregnancy or lactation. * Any condition limiting compliance or follow-up.